摘要
目的探讨拉氧头孢治疗急性尿路感染的临床疗效。方法选取医院2014年9月至2016年9月收治的急性尿路感染患者80例,随机分为治疗组和对照组,各40例。治疗组患者给予静脉滴注拉氧头孢2.0 g,每日2次;对照组患者给予静脉滴注头孢曲松2.0 g,每日2次。两组患者均治疗14 d后评价疗效。结果治疗组患者用药第4天及停药后第1,7天临床有效率分别为90.00%,97.50%,97.50%,分别高于对照组的67.50%,75.00%,75.00%,差异有统计学意义(P<0.05);治疗组患者用药第4天及停药后第1,7天细菌学有效率分别为94.74%,97.37%,97.37%,分别高于对照组的71.05%,73.68%,73.68%,差异有统计学意义(P<0.05);用药后,治疗组患者血浆降钙素原、C反应蛋白和脂多糖水平较对照组明显下降,差异有统计学意义(P<0.05);尿培养显示,拉氧头孢的敏感率最高(97.37%);两组患者不良反应发生率无明显差异(P>0.05)。结论拉氧头孢治疗急性尿路感染效果好、安全性高,可作为临床优选治疗方案。
Objective To investigate the clinical efficacy of Latamoxef in treating acute urinary tract infection. Methods Totally 80 patients with acute urinary tract infection from September 2014 to September 2016 were randomly divided into the treatment group and the control group,40 cases in each group. The treatment group was given intravenous infusion of Latamoxef 2.0 g,2 times /d;the control group was given intravenous ceftriaxone 2.0 g,2 times/d. Both groups were treated for 14 d,and the efficacies in the two group were evaluated after treatment. Results At the 4 d of medication and 1,7 d after treatment, the effective rates were 90. 00% , 97. 50% and 97.50% in the treatment group,which were significantly higher than 67.50% ,75.00% and 75.00% in the control group （P 〈 0.05）;the effective rate of bacteriology was 94.74% ,97.37% and 97.37% in the treatment group,which were significantly higher than 71.05% ,73.68% and 73.68% in the control group（P 〈 0.05）. After medication,the levels of plasma procalcitonin, C-reactive protein and lipopolysaccharide in the treatment group were significantly lower than those in the control group（P 〈 0. 05）; urine culture showed that the sensitivity of the cephalosporin was the highest（97.37% ）;there was no significant difference in the incidence of adverse reactions between the two groups（ P 〉 0. 05）. Conclusion Latamoxef in treating acute urinary tract infection is effective and safe,which can be used as a clinical optimal treatment.
出处
《中国药业》
CAS
2017年第6期31-34,共4页
China Pharmaceuticals
关键词
拉氧头孢
急性尿路感染
临床疗效
安全性
细菌学疗效
Latamoxef
urinary tract infection
clinical efficacy
safety
bacteriological effect
